In recent years, a potent neuroprotective agent, erythropoietin (EPO), has been demonstrated to enhance the permeability of astrocyte AQP4 and might directly lower the risk of astrocyte swelling in stroke and other brain disorders (Gunnarson et al., 2009). Here, AQP4 is linked to stroke disorder.